Intra-arterial vinblastine is well tolerated for the treatment of urothelial cell carcinomas and prostatic carcinomas in dogs

Objective To describe the treatment and outcome for dogs with lower urinary tract carcinoma or prostatic carcinoma treated with intra-arterial vinblastine. Animals 14 client-owned dogs from a single private referral center identified through a search of the medical records as having either urothelial cell carcinoma (n = 8) or prostatic carcinoma (6) treated with intra-arterial vinblastine from September 1, 2016, through September 30, 2023. Clinical Presentation The most commonly reported clinical signs were pollakiuria, stranguria, and hematuria alone or in combination. Median duration of clinical signs prior to vinblastine treatment was 5 weeks (range, 1 to 18 weeks). Median body weight and age at intra-arterial vinblastine treatment were 14.85 kg (range, 5.7 to 33.5 kg) and 8 years (range, 6 to 11 years). There were 9 castrated males and 5 spayed females. Results Vinblastine was successfully administered via the internal iliac arteries in all cases. Clinical outcome was reported in 10 dogs: 9 improved, and 1 had stable clinical signs. Restaging was available for 8 dogs, of which 2 of 8 were classified as having partial response, 4 of 8 stable disease, and 2 of 8 progressive disease. Clinical Relevance Intra-arterial vinblastine was well tolerated in dogs in this study and may contribute to rapid clinical improvement. Intra-arterial vinblastine shows promise in treating urothelial cell carcinoma and prostatic carcinoma in dogs; however, additional research is needed.

Authors

Institutions

Publication Details

Journal
American Journal of Veterinary Research
Published
2026-11-20
DOI
https://doi.org/10.2460/ajvr.26.07.0331
Primary Topic
Veterinary Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intra-arterial vinblastine is well tolerated for the treatment of urothelial cell carcinomas and prostatic carcinomas in dogs

Gerard McLauchlan, Laura Letwin, Jen O’Keeffe, Alex Horton et al.
2 links
American Journal of Veterinary Research
Veterinary Oncology Research
article

Intra-arterial vinblastine is well tolerated for the treatment of urothelial cell carcinomas and prostatic carcinomas in dogs

Gerard McLauchlan, Laura Letwin, Jen O’Keeffe, Alex Horton, Oriane Vigouroux
article en

Abstract

Objective To describe the treatment and outcome for dogs with lower urinary tract carcinoma or prostatic carcinoma treated with intra-arterial vinblastine. Animals 14 client-owned dogs from a single private referral center identified through a search of the medical records as having either urothelial cell carcinoma (n = 8) or prostatic carcinoma (6) treated with intra-arterial vinblastine from September 1, 2016, through September 30, 2023. Clinical Presentation The most commonly reported clinical signs were pollakiuria, stranguria, and hematuria alone or in combination. Median duration of clinical signs prior to vinblastine treatment was 5 weeks (range, 1 to 18 weeks). Median body weight and age at intra-arterial vinblastine treatment were 14.85 kg (range, 5.7 to 33.5 kg) and 8 years (range, 6 to 11 years). There were 9 castrated males and 5 spayed females. Results Vinblastine was successfully administered via the internal iliac arteries in all cases. Clinical outcome was reported in 10 dogs: 9 improved, and 1 had stable clinical signs. Restaging was available for 8 dogs, of which 2 of 8 were classified as having partial response, 4 of 8 stable disease, and 2 of 8 progressive disease. Clinical Relevance Intra-arterial vinblastine was well tolerated in dogs in this study and may contribute to rapid clinical improvement. Intra-arterial vinblastine shows promise in treating urothelial cell carcinoma and prostatic carcinoma in dogs; however, additional research is needed.

American Journal of Veterinary Research
Royal Surrey NHS Foundation Trust (GB)
Good health and well-being
Veterinary Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon